Business development and collaboration with strategic partners is an important pillar of Antibe’s growth strategy as we continually seek to source new product opportunities and monetize our existing portfolio.
Pain & Inflammation
Antibe has a promising pipeline of blockbuster drug candidates addressing pain and inflammation with its lead asset currently in Phase 2 of development (ATB-346). Antibe is strategically seeking regional partners to provide non-dilutive sources of funding and monetize its drug platform through royalty and milestone revenue.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales, marketing and distribution of tissue regenerative products for oral and maxillofacial surgery. Antibe is actively looking for innovative pre-approval and commercial opportunities to expand its portfolio in the field of dental regenerative medicine.
To discuss partnering opportunities please contact:
VP, Corporate Development